Project Grant R01AR085702
- Federal Project Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $1.85 million Project Grant to the University of California, San Diego on September 15, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award supports a three-year research initiative (completion date August 31, 2028) investigating the role of lysine acetylation in skeletal muscle contractile function. The research will...
- Federal Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded Columbia University's Health Sciences Division a $3.06 million Project Grant effective September 1, 2025, through August 31, 2028, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). This research initiative will produce scientific findings identifying the molecular mechanisms underlying skeletal muscle weakness associated with heart failure,...
- Federal Project Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $554,797 Project Grant to The University of Kentucky Research Foundation, effective September 1, 2025 through May 31, 2030, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). This research initiative will advance fundamental understanding of myonuclear turnover dynamics in adult skeletal muscle, a critical gap in musculoskeletal...
- Federal Project Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $351,000 Project Grant to The Washington University beginning September 1, 2025, and extending through July 31, 2030, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). This award supports research investigating the role of alternative splicing in facioscapulohumeral muscular dystrophy (FSHD), a prevalent form of muscular dystrophy...
- Federal Project Grant Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded the University of Pittsburgh a $1.61 million Project Grant (CFDA 93.846: Arthritis, Musculoskeletal and Skin Diseases Research) effective September 15, 2025, through August 31, 2029, to investigate the relationship between muscle characteristics and bone health in older adults. The project examines comprehensive muscle associations—including maximal ATP (adenosine triphosphate)...
- Federal Project Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $198,263 Project Grant to the University of Nebraska (Board of Regents) on September 5, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award supports research through August 31, 2027, investigating the role of Mitsugumin 53 (MG53) protein in preventing disuse-induced muscle atrophy and sarcopenia. The research project...
- Federal Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded President and Fellows of Harvard College a $676,841 project grant effective August 1, 2025, through July 31, 2030, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The project, "Leveraging Human Musculoskeletal Development to Identify Causal Disease Variants," will deliver comprehensive transcriptomic and epigenomic mapping of human...
- Federal Project Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a project grant of $323,918 to the University of Missouri at Kansas City, with an award date of September 15, 2025 and completion date of July 31, 2030, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). This research project investigates isoform-specific functions of the RNA-binding protein Bruno1 (BRU1) in Drosophila melanogaster...
- Federal Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded University of California, Los Angeles a $401,625 Project Grant (CFDA 93.846: Arthritis, Musculoskeletal and Skin Diseases Research) effective March 15, 2026, with completion targeted for December 31, 2029. This ancillary mechanistic study is embedded within an ongoing randomized clinical trial (PROFFI) and will evaluate the effects of exercise combined with senolytic therapy on...
- Federal Project Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded the University of Pennsylvania a project grant of $857,127 (awarded June 3, 2025, with completion targeted for April 30, 2030) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The research project, "Mitochondrial Respiration and the Biology of Growth Plate Chondrocytes," investigates the role of bioenergetic...
Baylor College of Medicine received a $679,931 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), effective April 20, 2026, with a completion date of March 31, 2031. The research investigates the role of SPEG-regulated sarcoplasmic reticulum calcium leak in muscle function and disease pathophysiology, focusing on excitation-contraction coupling (ECC) proteins and their relationship to congenital myopathies. The project will elucidate mechanisms by which the SPEG kinase regulates calcium leak through the RYR1 calcium release channel via phosphorylation at serine 2902, and will assess whether this phosphorylation site modification improves muscle and mitochondrial function in myopathy models and mitigates age-related muscle decline. The research deliverables include mechanistic characterization of SPEG kinase domain function, evaluation of the S2902D phosphomimetic mutation's effects on muscle performance across multiple myopathy models, and assessment of a therapeutic compound (S107) for off-target effects and efficacy in treating calcium leak-initiated versus triad disruption-initiated myopathies. The project will generate preclinical data on novel therapeutic targets for muscle disorders characterized by abnormal sarcoplasmic reticulum calcium handling, contributing to the NIAMS program's objectives of advancing understanding of musculoskeletal disease mechanisms and developing innovative treatment approaches.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $679.9k | 4/21/26 |